Protagonist Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 112
- Market Cap
- $2.4B
- Introduction
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia
Phase 2
Completed
- Conditions
- Ineffective Erythropoiesisβ-thalassemiaChronic Anemia
- Interventions
- Drug: PTG-300
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Protagonist Therapeutics, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT03802201
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇬🇷University General Hospital of Patras, Patras, Achaia, Greece
Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis
Phase 2
Terminated
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: PTG-100Drug: Placebo
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Protagonist Therapeutics, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT02895100
- Locations
- 🇺🇦
Site Reference ID/Investigator # 547, Zaporizhzhya, Ukraine
🇺🇦Site Reference ID/Investigator # 509, Kharkov, Ukraine
🇺🇸Site Reference ID/Investigator # 101, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath